288 related articles for article (PubMed ID: 19265025)
1. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Rosenson RS; Otvos JD; Hsia J
Diabetes Care; 2009 Jun; 32(6):1087-91. PubMed ID: 19265025
[TBL] [Abstract][Full Text] [Related]
2. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
3. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Deedwania PC; Gupta M; Stein M; Ycas J; Gold A;
Am J Cardiol; 2007 Jun; 99(11):1538-43. PubMed ID: 17531577
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
6. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
8. Effect of two intensive statin regimens on progression of coronary disease.
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
[TBL] [Abstract][Full Text] [Related]
9. Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
Herregods MC; Daubresse JC; Michel G; Lamotte M; Vissers E; Vandenhoven G;
Acta Cardiol; 2008 Aug; 63(4):493-9. PubMed ID: 18795588
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Wolffenbuttel BH; Franken AA; Vincent HH;
J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
[TBL] [Abstract][Full Text] [Related]
11. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
12. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
Stein EA; Strutt K; Southworth H; Diggle PJ; Miller E;
Am J Cardiol; 2003 Dec; 92(11):1287-93. PubMed ID: 14636905
[TBL] [Abstract][Full Text] [Related]
13. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
14. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Kakuda H; Matoba M; Nakatoh H; Nagao S; Takekoshi N
Scand J Clin Lab Invest; 2014 Jun; 74(4):285-95. PubMed ID: 24564634
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Betteridge DJ; Gibson JM
Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
[TBL] [Abstract][Full Text] [Related]
16. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Bullano MF; Kamat S; Wertz DA; Borok GM; Gandhi SK; McDonough KL; Willey VJ
Am J Health Syst Pharm; 2007 Feb; 64(3):276-84. PubMed ID: 17244877
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Ballantyne CM; Jones PH; Kelly MT; Setze CM; Lele A; Thakker KM; Stolzenbach JC
Cardiovasc Drugs Ther; 2011 Feb; 25(1):59-67. PubMed ID: 21416219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
